We investigated whether daily oral washings with recombinant human granulocyte-macrophage colonystimulating factor (rhGM-CSF) solution improved grade III-IV oropharyngeal mucositis (OM) in patients with hematological malignancies undergoing stem cell transplantation. Forty-one consecutive patients (21 males and 20 females, median age (range) 44 (16-69) years) were prospectively randomized to perform daily mouth-washes with either a 400 g rhGM-CSF (Molgramostin, Schering-Plough) solution (group A, n ‫؍‬ 18) or with a saline solution (group B, n ‫؍‬ 23). Primary end-points were the intensity of OM, night rest quality and characteristics of food intake. Secondary end-points were need for and duration of parenteral nutrition, oral and intravenous analgesic requirements, incidence of viral or fungal oral infections and development of neutropenic fever. No differences were found between the placebo and rhGM-CSF-treated groups regarding overall duration of OM, maximum grade, reduction in at least one grade of OM (nine patients (56%) in group A vs 13 patients (68%) in group B), reduction of spontaneous or swallowing-induced pain, improvement in oral food intake, use of parenteral nutrition or use of systemic analgesics. In conclusion, mouth-washings with a 400 g of rhGM-CSF solution do not improve severe OM in hematological patients undergoing stem cell transplantation.
Oral mucositis (OM) is one of the most frequent sideeffects of patients receiving high-dose chemo/radiotherapy and stem cell transplantation. 1 Mucosal damage is a multistep process involving the release of inflammatory cytokines and DNA damage leading to a breakdown of mucosal barriers and an increased risk of infections. 2 It not only causes pain and makes oral food intake difficult but also produces sleep disorders. Risk factors for OM severity are classified as either patient-related or treatment-related; age, chronic periodontal disease, xerostomia and nutritional status are included in the former group, while chemotherapy schedule and the use of radiotherapy (RT) are therapy-related. 3 Many studies have shown the relationship between granulocyte recovery and OM resolution. 4, 5 Although many drugs have been investigated as prophylactic or therapeutic agents for OM improvement, no effective treatment has yet been established. In several pilot studies, granulocyte-macrophage colony-stimulating factor (GM-CSF) or granulocyte colony-stimulating factor (G-CSF) have been found to significantly reduce the severity and duration of OM when administered subcutaneously as they shorten the absolute neutropenic period. [6] [7] [8] [9] Furthermore, several studies have also shown that these cytokines influence the migration and proliferation of non-hematological cells such as keratinocytes, 4 claimed to have a significant effect on mucosal repair. On the other hand, other authors have shown an increase in the incidence of OM with the systemic use of these cytokines. 1, 10 Growth factors have also been used topically for prevention or treatment of OM. Although one randomized study which included non-Hodgkin's lymphoma (NHL) patients treated with high-dose methotrexate showed a small reduction in the severity of OM using topically applied G-CSF, 11 in their recent study, van der Lelie and coworkers found no significant difference in OM with respect to a placebo group when using a solution of 300 g rhGM-CSF in a 2% methylcellulose gel from day ϩ1 to neutrophil recovery in patients undergoing stem cell transplantation.
12
In order to further investigate a potential benefit of daily oral mouth-washings of rhGM-CSF on grade III-IV OM due to high-dose chemo/radiotherapy, we performed a prospective double-blind randomized trial comparing 400 g of a saline rhGM-CSF solution with placebo, in patients undergoing stem cell transplantation.
Patients and methods

Patients
Between October 1998 and March 2001, 41 consecutive patients who developed OM grades III-IV of the WHO scale after undergoing autologous or allogeneic stem cell transplantation after a myeloablative conditioning regimen (Table 1) , were included in this study. The main clinical characteristics of patients included in the rhGM-CSF arm (group A) and in the placebo arm (group B) are shown in Table 2 . There were 21 males and 20 females with a median age of 44 years old (range, 16 to 69). Ten patients were diagnosed with acute leukemia, 11 with chronic myeloid leukemia, 5 with chronic lymphoproliferative disorders, 10 AL ϭ acute leukemia; CL ϭ chronic leukemia; MDS ϭ myelodysplastic syndromes; LPDs ϭ lymphoproliferative disorders; MM ϭ multiple myeloma; Cy ϭ cyclophosphamide; TBI ϭ total body irradiation; BM ϭ bone marrow; PB ϭ peripheral blood; Mtx ϭ methotrexate; aGVHD ϭ acute graftversus-host disease.
with multiple myeloma and 3 with myelodysplastic syndrome. Twenty-five patients underwent autologous stem cell transplantation (ASCT) and 16 allogeneic transplantation, four of the latter being from an unrelated donor.
Mobilized peripheral blood was used as the source of hematopoietic stem cells in 28 patients and bone marrow in the remaining 11 patients. Several conditioning regimens were used: cyclophosphamide (60 mg/kg i.v. ϫ 2 days) plus hyperfractionated total body irradiation (TBI) ( i.v. on day ϩ1 and 10 mg/m 2 i.v. on days ϩ3 and ϩ6) was used for acute graft-versus-host disease (GVHD) prophylaxis. All patients were nursed in single rooms with filtered air with positive pressure and treated with acyclovir 800 mg p.o. twice a day as viral prophylaxis. Allogeneic recipients also received antimicrobial prophylaxis with norfloxacine 400 mg p.o. twice a day which was switched to cyprofloxacine 250 mg i.v. twice a day, when OM developed, and fungal prophylaxis with fluconazol 200 mg p.o. every day. Broad-spectrum antibiotic therapy with cefepime 1 g every 8 h i.v. or imipenem 500 mg every 6 h i.v. was started with the development of neutropenic fever. None of the patients included in the study received intravenous G-CSF except those with multiple myeloma who received G-CSF at a dose of 5 g/kg s.c. from day ϩ7 to neutrophil recovery as part of a multicenter national protocol. Parenteral nutrition was started when patients were unable to eat for longer than 3 days. Morphine was started when non-opioid analgesics were insufficient.
The study protocol was approved by the institutional ethics committee and all patients gave written informed consent.
Methods rhGM-CSF (molgramostin):
The drug was kindly supplied by Schering-Plough, Barcelona, Spain. Once the patients had given their informed consent they were randomized to receive the study drug or placebo. We used 400 g of rhGM-CSF dissolved in 200 ml of saline solution in the study group (group A) whereas the control group (group B) received 200 ml of saline solution only. The dose used in this study was chosen after reviewing maximal doses administered in previously performed smaller trials. Both patient randomization and drug preparation were performed in the Pharmacy Department. There were no differences in color, flavor or taste of the study drug and the placebo. Both groups performed mouth-washings with the solution three times a day for 30 min without swallowing, over a period of 5 days after inclusion in the protocol. Once the solution had been taken, the patients were asked to avoid any oral intake for 1 h. Apart from these measures, patients followed the standard protocol of mouth care at our institution with tooth brushing after each meal and rinsing of the oral cavity with 0.9% saline or, in cases of inflammation, 0.12% chlorhexidine four times daily.
Evaluation: OM was evaluated daily by two-team physicians using four different methods: the WHO toxicity score grading mucositis from 0 to IV, 13 a visual analog scale (EVA scale) allowing the patient to score spontaneous and swallowing-induced pain from 0 (no pain) to 10 (the most severe pain) thrice daily, sleep quality evaluated once a day as good, intermediate or poor and oral food intake evaluated three times a day as no food intake, liquid diet, soft diet or normal diet.
Other potential beneficial effects of rhGM-CSF mouth washes were also evaluated by recording number of documented infectious episodes, days with fever, fungal and viral oral infections and the need for broad-spectrum intravenous antibiotics, parenteral nutrition or opioids.
Statistical analysis:
Results are expressed by mean Ϯ standard deviation. Comparison between qualitative variables was performed using the chi-square test and between quantitative variables by means of the Mann-Whitney U test. P Ͻ 0.05 was considered of statistical significance.
Results
Six patients were randomized but later excluded due to early death in three, patient refusal in two and need for noninvasive ventilation upon protocol inclusion in one. Sixteen patients in the study group and 19 in the control group completed the protocol. Both groups were well balanced with respect to age, sex, primary diagnosis and phase of the disease, source of hematopoietic stem cells, type of donor and conditioning regimen.
Bone Marrow Transplantation
Mucositis improvement
There were no statistically significant differences in overall duration of OM (12.5 Ϯ 3.4 days in group A vs 11.4 Ϯ 4 days in group B) or duration of the maximum grade of OM (3.6 Ϯ 1.6 days in group A vs 3.6 Ϯ 1.5 days in group B) ( Table 2) . Reduction in at least one grade of OM was observed in seven patients (56%) in group A and in six patients (68%) in group B (P ϭ NS). Spontaneous and swallowing-induced mouth pain evaluated with the EVA scale and improvement of sleep quality were also similar in both groups. At the beginning of the treatment protocol, two patients (12%) from the GM-CSF group and 10 patients (53%) from the control group were treated with occasional i.v. morphine (P ϭ 0.045) and three patients in each group were receiving morphine by continuous infusion pump (PCA). A significant increment in the need for PCA morphine was observed in the GM-CSF-treated group (eight patients (50%)) with respect to the control group (two patients (10%), P ϭ 0.02), probably due to the fact that fewer patients in the GM-CSF group were being treated with PCA morphine at the beginning of the protocol and that GM-CSF mouth-washings did not significantly modify the natural evolution of OM.
Oral intake, need for parenteral nutrition
Thirty-seven percent of patients from group A and 21% from group B were unable to swallow even a liquid diet due to OM at the beginning of the protocol. No statistically significant differences were observed between the two groups regarding the improvement of oral intake during the protocol: eight patients (50%) from group A vs 12 patients from group B (63%) improved their diet by one grade. Six patients from the rhGM-CSF group (37%) and seven (37%) from the placebo group needed parenteral nutrition during transplantation. There were no statistically significant differences in the duration of total parenteral nutrition between both groups of patients.
Incidence of oral and systemic infections
Severe neutropenia (Ͻ0.5 ϫ 10 9 /l granulocytes in peripheral blood) was present at the beginning of the study period in all patients. The incidence of oral infections, fever and positive blood cultures was similar in both groups and no difference was observed in the use of systemic empirical antibiotics. There were no significant differences between duration of severe neutropenia, incidence of neutropenic fever and documented severe infections and incidence of oral infections (see Table 3 ).
Discussion
Grade III to IV OM is a major dose-limiting toxicity of the conditioning protocols used in stem cell transplantation programs and affects up to 90% of patients in some studies. 1 It causes significant discomfort and stress in transplanted patients, worsens night sleep quality and deteriorates oral intake. It may lead to the need for a wide variety of analgesics, including opioids, and to the use of total parenteral nutrition. OM also increases the incidence of systemic infectious episodes due to the disruption of the natural mucosal barrier. Although no effective treatment for OM has yet been found, several studies have demonstrated that subcutaneous administration of colony-stimulating factors (G-CSF or GM-CSF) can improve OM. Furthermore, topical administration of GM-CSF improves OM in patients receiving chemo/radiotherapy for head and neck cancer 14, 15 and breast cancer. 16 In order to assess the effect of topical rhGM-CSF on OM secondary to high-dose chemo/radiotherapy in hematological patients, we conducted a prospective randomized double-blind trial including 41 consecutive patients. Information on the possible beneficial effect of growth factors on OM in hematological patients is scarce. Karthaus et al 11 found a marginal beneficial effect of topical G-CSF in a small randomized trial of eight patients receiving methotrexate-containing chemotherapy for high-grade NHL. There are several differences between this study and ours. Karthaus started G-CSF mouthwashes before OM developed and evaluated the incidence and maximal grade of this complication. Furthermore, the patient population analyzed is different. A less intense OM is to be expected after a rescue treatment for NHL in relation to OM developing after a conditioning regimen for stem cell transplantation, as in our protocol. van der Lelie et al 12 did not find any beneficial effect of 300 g rhGM-CSF in an aqueous methylcellulose gel in a prospective randomized trial which included 36 patients undergoing a stem cell transplantation. There are also several differences between van der Lelie's trial and our own. In the Dutch trial, all patients undergoing stem cell transplantation were included, not only those developing grade III to IV OM as in our study. rhGM-CSF was given at a dose of 300 g in a methylcellulose gel, twice daily, from day ϩ1 to the end of the neutropenic period. In our trial, rhGM-CSF dose was higher, 400 g, the basis of the solution was saline solution and it was used three times a day for 5 days only after entering the protocol, and not during the whole neutropenic period. In our study, there were no drop-outs due to the unpleasantness of the medication, while in van der Lelie's trial eight of the 36 patients discontinued the drug at an early stage due to its taste. As in the Dutch trial, we were unable to find any significant difference between the placebo and the rhGM-CSF-treated group in terms of overall duration and reduction of OM after transplantation, reduction of i.v. analgesia requirements, improvement in oral intake and sleep quality. Nevertheless, the number of patients included in both arms is small and other studies are needed to confirm our results.
In conclusion, we were unable to find any benefit in the daily administration of a rhGM-CSF solution to improve OM in patients undergoing stem cell transplantation and developing grade III to IV OM. The topical administration of rhGM-CSF is insufficient to treat or even to prevent the development of OM, as previously demonstrated by others.
12 Maybe, the i.v. administration of other wellknown cytoprotectors can be used to significantly decrease the incidence and severity of this side-effect of high-dose chemo/radiotherapy. Nevertheless, the avoidance of iv methotrexate as acute GVHD prophylaxis in the CD34 ϩ cell positively selected allogeneic transplantation or the use of reduced conditioning regimens also in the allogeneic setting are presently reducing this complication in the total of transplanted patients.
